DLN
DividendWisdomTree U.S. LargeCap Dividend Fund
WisdomTree · Tracks WisdomTree U.S. LargeCap Dividend Index · Inception Jun 16, 2006
Composite score
Based on a 0.28% expense ratio.
Based on $6.14B in net assets.
Top-10 holdings represent 24.7% of net assets.
Dividend base · ETF wrapper · 1.76% TTM yield.
The composite is a weighted average of the four core sub-scores above (cost, tax efficiency, liquidity, concentration). Missing sub-scores fall back to the per-category median when the category has at least 50% data coverage, so funds without (e.g.) parsed N-PORT holdings aren't accidentally boosted by renormalization. Tracking quality is shown where computable but isn't currently part of the composite weighting. See methodology for formulas, the tracking-quality partial-coverage rationale, and the dimensions we deliberately don't score (methodology v0.5.1).
Use DLN in our tools
Tool · Cost
Compare DLN's fee against another fund
Compounds the 0.28% expense ratio against a peer over decades.
Tool · Overlap
Compare DLN's holdings with peers
Pairwise holdings heatmap, pre-loaded with similar Dividend funds.
Tool · TLH
Find a tax-loss harvesting partner for DLN
Ranks every catalog fund by holdings overlap, flags wash-sale risk.
Tool · Placement
Where should this fund live across your accounts?
Asset-location optimizer — places each fund in taxable / tax-deferred / Roth.
Top holdings
| # | Holding | Weight |
|---|---|---|
| 1 | NVIDIA Corp. | 3.38% |
| 2 | JPMorgan Chase & Co. | 3.29% |
| 3 | Microsoft Corp. | 2.96% |
| 4 | Apple Inc. | 2.95% |
| 5 | Exxon Mobil Corp. | 2.77% |
| 6 | CHEVRON CORP | 2.27% |
| 7 | Johnson & Johnson | 2.11% |
| 8 | Broadcom Inc | 1.91% |
| 9 | AbbVie Inc. | 1.63% |
| 10 | Philip Morris International Inc. | 1.41% |
Compare DLN with another fund
Or skim the closest-overlap funds below.
Similar ETFs by holdings overlap
Open DLN at a brokerage
Affiliate links — opening an account through these earns PlainIndex a one-time referral. Scoring is computed before any affiliate consideration; see our methodology and funding disclosure.